The purpose of this study is to determine what good or bad effects the drug, ramucirumab, may have on patients who have colon or rectal cancer that has spread to other organs or has come back locally with the first choice of treatment. The study is also trying to determine whether it is safe and effective for patients to receive this treatment.
Irinotecan and cetuximab are standard treatments for patients who have metastatic colon or rectal cancer, who have already received one previous chemotherapy that is no longer working, and do not have a specific type of mutation (alteration) of the K-ras gene in their tumor. Ramucirumab is an experimental drug that has been found to block a pathway that allows tumors to grow in animals and humans. Ramucirumab is an FDA approved drug for the treatment of gastric and GE cancers however is not yet approved for treatment of colorectal cancer. It is unknown if adding a drug of this type to a standard second line therapy for colorectal cancer is beneficial.